Testosterone Testing in Men: When to Check, How to Interpret, and the Prescribing Minefield of TRT

 

Testosterone Testing in Men: When to Check, How to Interpret, and the Prescribing Minefield of TRT

A total testosterone of 280 at 8 AM in a symptomatic man means something. A total testosterone of 280 drawn at 3 PM after a night of poor sleep means almost nothing.

Testosterone replacement therapy (TRT) is one of the fastest-growing prescriptions in men's health, driven by direct-to-consumer marketing, telehealth "optimization" clinics, and patient demand. For primary care NPs, this creates a two-sided problem: underdiagnosis of true hypogonadism in men who would benefit from treatment, and overprescription of testosterone in men who don't meet diagnostic criteria and face real risks. Getting the workup right is the foundation of safe prescribing.

The Physiology: What Testosterone Does and How It's Regulated

The hypothalamic-pituitary-gonadal (HPG) axis works as a feedback loop: GnRH from the hypothalamus stimulates LH and FSH from the anterior pituitary, LH stimulates Leydig cells in the testes to produce testosterone, and testosterone feeds back to suppress GnRH and LH. Understanding this loop is essential because it determines whether hypogonadism is primary (testicular failure, high LH) or secondary (pituitary/hypothalamic dysfunction, low/normal LH)—and the distinction changes the workup and treatment approach entirely.

Testosterone circulates in three forms: tightly bound to sex hormone-binding globulin (SHBG, ~44%), loosely bound to albumin (~54%), and free/unbound (~2–3%). Free testosterone plus albumin-bound testosterone together constitute "bioavailable testosterone"—the fraction that is biologically active. Total testosterone measures all three forms. In conditions that alter SHBG (and there are many), total testosterone can be misleading.

When to Test: The Appropriate Indications

Test for Hypogonadism When

• Specific symptoms are present: Decreased libido, erectile dysfunction, reduced morning erections, fatigue, decreased energy, loss of muscle mass/strength, increased body fat (especially visceral), depressed mood, difficulty concentrating, gynecomastia, decreased bone mineral density/fragility fractures, infertility, decreased testicular volume
• Conditions associated with hypogonadism: Type 2 diabetes (prevalence of hypogonadism ~25–40%), obesity (BMI >30, especially >40), metabolic syndrome, HIV/AIDS, chronic opioid use, glucocorticoid therapy, pituitary disease/mass, Klinefelter syndrome (47,XXY), prior testicular injury/orchitis/torsion, prior chemotherapy or radiation, hemochromatosis, obstructive sleep apnea

Do NOT screen asymptomatic men. The AUA, Endocrine Society, and ACP all recommend against population-based testosterone screening. Testing should be symptom-driven.

How to Test: Getting It Right the First Time

Step 1: Total Testosterone (Morning Draw)

The Timing Rule

Testosterone follows a circadian rhythm, peaking between 6–10 AM and declining 20–25% by afternoon. A total testosterone drawn at 3 PM will be significantly lower than the same man's 8 AM level. Always draw between 6–10 AM, fasting, after a normal night of sleep. Acute illness, sleep deprivation, recent heavy exercise, and alcohol use within 24 hours all suppress testosterone transiently and should prompt rescheduling. In men over 40, the circadian variation blunts somewhat, but morning draw remains standard practice.

• Test: Total testosterone by liquid chromatography-tandem mass spectrometry (LC-MS/MS). This is the gold standard. Immunoassay methods are less accurate, especially at low levels. If your lab uses immunoassay, be aware of potential inaccuracy and consider sending to a reference lab.
• Confirm with a second sample: A single low total testosterone is not diagnostic. The Endocrine Society requires two morning total testosterone levels on separate days before diagnosing hypogonadism. Up to 30% of men with an initially low level will have a normal level on repeat testing.

Step 2: Classify the Level

Total Testosterone	Interpretation	Next Step
>350 ng/dL	Normal for most assays and guidelines	Testosterone deficiency is unlikely as the cause of symptoms. Investigate other etiologies (depression, sleep apnea, thyroid, anemia).
250–350 ng/dL	Equivocal / "gray zone"	Check free testosterone (or calculate it) AND SHBG. If free T is low, hypogonadism is supported. If free T is normal, the low total T is due to low SHBG, not true deficiency.
<250 ng/dL	Unequivocally low	Confirm on a second morning draw. If confirmed, proceed with classification (primary vs. secondary) and evaluate for underlying causes before prescribing.

The SHBG Confounders

SHBG binds testosterone tightly, making it biologically unavailable. Conditions that raise SHBG inflate total testosterone (making the man appear replete when he isn't), and conditions that lower SHBG deflate total testosterone (making the man appear deficient when free T is actually normal).

• SHBG increases (total T falsely reassuring): aging, liver disease/cirrhosis, hyperthyroidism, anticonvulsants (phenytoin, carbamazepine), HIV, estrogen therapy, anorexia
• SHBG decreases (total T falsely low): obesity, type 2 diabetes, metabolic syndrome, hypothyroidism, nephrotic syndrome, exogenous androgens, glucocorticoids, GH excess

In any man with obesity, diabetes, or a total T in the 250–350 gray zone, you must check free testosterone or SHBG to interpret the total T accurately. Calculated free testosterone (using the Vermeulen equation with total T, SHBG, and albumin) is preferred over direct free T immunoassay, which is notoriously inaccurate.

Step 3: Primary vs. Secondary Hypogonadism

Type	FSH/LH	Cause	Key Workup
Primary (Hypergonadotropic)	Elevated LH and FSH (the pituitary is screaming at the testes and they're not responding)	Klinefelter syndrome (47,XXY), prior orchitis (mumps), testicular torsion/trauma, chemotherapy/radiation, cryptorchidism, age-related (late-onset hypogonadism)	Karyotype if <40 with primary hypogonadism (Klinefelter is the most common genetic cause, ~1 in 600 men, and the majority are undiagnosed). Testicular exam. Semen analysis if fertility desired.
Secondary (Hypogonadotropic)	Low or inappropriately normal LH and FSH	Pituitary adenoma (prolactinoma most common), hemochromatosis, Kallmann syndrome, obesity, opioid use, glucocorticoids, chronic illness, idiopathic	Prolactin (elevated = pituitary adenoma until proven otherwise). Iron/ferritin (hemochromatosis is a treatable cause). MRI of the pituitary if prolactin elevated, very low testosterone (<150), or signs of mass effect (visual field changes, headache). Evaluate for other pituitary hormone deficiencies (cortisol, TSH).

Never Skip the Classification

Prescribing TRT without checking LH/FSH is a missed opportunity to diagnose a prolactinoma, hemochromatosis, or Klinefelter syndrome—all of which have specific treatments beyond testosterone. A prolactinoma causing secondary hypogonadism may be cured with cabergoline. Hemochromatosis causing secondary hypogonadism is treated with phlebotomy, and testosterone may recover. LH, FSH, and prolactin are mandatory before prescribing TRT.

The Complete Pre-TRT Workup

Test	Why
Total testosterone (AM, ×2)	Confirm deficiency on two separate morning draws
Free testosterone (calculated) or SHBG	Clarify equivocal total T; essential in obesity, diabetes, liver disease
LH, FSH	Classify primary vs. secondary. Identify treatable pituitary/hypothalamic causes.
Prolactin	Screen for prolactinoma (most common secretory pituitary adenoma in men)
CBC (hemoglobin/hematocrit)	Baseline before TRT (testosterone stimulates erythropoiesis; polycythemia is the most common adverse effect). Hematocrit >50% is a relative contraindication to starting TRT.
PSA	Baseline prostate cancer screening. TRT is contraindicated in known/suspected prostate cancer. PSA >4 (or >3 in high-risk men) warrants urology referral before starting TRT.
Lipid panel	Baseline cardiovascular risk assessment
BMP	Baseline renal function
DEXA scan	If osteoporosis or fragility fracture is the presenting symptom
Iron/ferritin	Screen for hemochromatosis if secondary hypogonadism
Semen analysis	If fertility is desired. TRT suppresses spermatogenesis and is NOT appropriate for men who want to conceive.
TSH	Hypothyroidism mimics hypogonadal symptoms and raises SHBG

Testosterone Replacement: Formulations and Monitoring

Formulation	Route	Typical Dosing	Key Considerations
Testosterone cypionate	IM injection	100–200 mg every 1–2 weeks	Most common, least expensive. Peak-trough fluctuations (mood/energy swings). Self-injection taught to patients. Draw trough levels (just before next injection).
Testosterone enanthate	IM injection	100–200 mg every 1–2 weeks	Similar pharmacokinetics to cypionate. Interchangeable in practice.
Testosterone undecanoate (Aveed)	IM injection	750 mg initially, at 4 weeks, then every 10 weeks	Longer intervals. Requires REMS program (risk of pulmonary oil microembolism, anaphylaxis). Must be administered in clinic with 30-min observation.
Topical gel (AndroGel, Testim, Vogelxo)	Transdermal	1–4 pumps daily (varies by product)	Steady-state levels. Risk of transference to women/children through skin contact (FDA black box warning). Apply to shoulders/upper arms, wash hands, cover with clothing. Draw levels 2–4 hours after application.
Testosterone patch (Androderm)	Transdermal	2–4 mg nightly	Skin irritation common (~30%). Apply to back, abdomen, thigh, or upper arm. Rotate sites.
Nasal gel (Natesto)	Intranasal	5.5 mg per nostril TID	Short-acting. May preserve spermatogenesis better than other formulations (less HPG suppression due to pulsatile delivery). Nasal irritation.
Subcutaneous pellets (Testopel)	Implant	150–450 mg every 3–6 months	Inserted in office. Steady levels. Risk of pellet extrusion, infection at insertion site. Cannot adjust dose easily once implanted.
Oral testosterone undecanoate (Jatenzo)	Oral	158–396 mg BID with food	Newer formulation. Absorbed via lymphatic system (avoids first-pass hepatotoxicity of older oral forms). BP monitoring required (increases systolic ~3–5 mmHg).

Monitoring on TRT

Test	When	Target / Action
Total testosterone	3–6 months after initiation or dose change, then annually	Goal: mid-normal range (400–700 ng/dL). For injections, draw trough level. For gels, draw 2–4 hours post-application.
Hematocrit	3–6 months, then every 6–12 months	Hematocrit >54% = hold TRT, reduce dose, or phlebotomize. Polycythemia is the most common adverse effect and increases thrombotic risk (stroke, PE, DVT).
PSA	3–6 months, 12 months, then per screening guidelines	PSA rise >1.4 ng/mL within 12 months of starting TRT = urology referral. TRT does not cause prostate cancer, but may accelerate growth of occult cancer.
Lipid panel	6–12 months	TRT may lower HDL. Monitor cardiovascular risk profile.
Estradiol	If gynecomastia, nipple tenderness, or mood symptoms develop	Testosterone aromatizes to estradiol. Elevated estradiol (>40–50 pg/mL) may require dose reduction. Routine AI (anastrozole) use is NOT recommended by guidelines.
BMP	Annually	Renal function monitoring
Bone density (DEXA)	1–2 years if osteoporosis was the indication	Expect improvement in BMD within 12–24 months
Symptom assessment	Every visit	If no symptom improvement at 3–6 months with adequate levels, reconsider the diagnosis. Low testosterone may not have been the cause.

Contraindications to TRT

Do Not Prescribe TRT If

• Desire for fertility: Exogenous testosterone suppresses LH/FSH, which suppresses spermatogenesis. TRT is a form of male contraception. For hypogonadal men who want to conceive, use clomiphene citrate (off-label, stimulates endogenous testosterone production via HPG axis) or hCG (mimics LH, stimulates testicular testosterone production without suppressing spermatogenesis).
• Known or suspected prostate cancer (absolute)
• Breast cancer in men (absolute)
• Hematocrit >50% at baseline (relative; evaluate for other causes of polycythemia first)
• Untreated severe obstructive sleep apnea: TRT can worsen OSA. Treat OSA first, then reassess symptoms.
• Uncontrolled heart failure (NYHA Class III–IV): Risk of fluid retention
• PSA >4 ng/mL (or >3 in high-risk men) without urological evaluation
• Recent (within 3–6 months) major cardiovascular event: MI, stroke, DVT, PE. The cardiovascular safety of TRT is addressed by the TRAVERSE trial (see below).

The TRAVERSE Trial: Cardiovascular Safety Resolved

Practice-Changing Evidence

The TRAVERSE trial (2023, NEJM) was the first large, randomized, placebo-controlled cardiovascular outcomes trial of TRT. In 5,246 men aged 45–80 with hypogonadism and established or high-risk cardiovascular disease, testosterone gel did not increase the incidence of major adverse cardiovascular events (MACE: CV death, MI, stroke) compared to placebo over a median follow-up of 33 months. This resolved a decade of uncertainty following the 2010 TOM trial and observational studies that raised cardiovascular concerns. The 2024 updated AUA and Endocrine Society guidelines reflect this data: TRT is not contraindicated in men with stable cardiovascular disease who meet diagnostic criteria for hypogonadism. However, the trial did confirm increased rates of atrial fibrillation, AKI, and pulmonary embolism in the TRT group, so monitoring remains essential.

The Opioid-Induced Hypogonadism Problem

Chronic opioid use suppresses GnRH pulsatility, causing secondary hypogonadism in an estimated 50–90% of men on long-term opioids. This is one of the most underrecognized causes of testosterone deficiency in primary care.

• Mechanism: Opioids suppress the HPG axis centrally. LH and FSH are low. Testosterone is low.
• Symptoms: Sexual dysfunction, fatigue, depression, osteoporosis—often attributed to the underlying pain condition rather than the opioid.
• Management: First step is opioid dose reduction or discontinuation (with appropriate tapering). If opioids cannot be reduced, TRT may be considered, but it treats the symptom, not the cause. Alternatives: clomiphene (restores endogenous production in some patients).
• Screen all men on chronic opioid therapy (≥3 months) with a morning total testosterone if they report sexual dysfunction, fatigue, or mood changes.

Obesity and Testosterone: The Chicken-and-Egg Problem

Functional Hypogonadism

Obesity is the most common cause of low total testosterone in men. Excess adipose tissue aromatizes testosterone to estradiol (lowering T), and obesity lowers SHBG (making total T appear lower while free T may be preserved). This creates a functional or "reversible" hypogonadism. Weight loss of 5–10% can increase total testosterone by 50–100 ng/dL without TRT. Bariatric surgery patients often normalize testosterone. Before prescribing TRT to an obese man with a borderline-low total T, check free testosterone and counsel on weight loss. If free T is normal, the low total T is an SHBG effect, not true deficiency. The AUA 2024 guidelines recommend lifestyle intervention as first-line for obese men with functional hypogonadism.

Testosterone in Older Men: The Age-Related Decline Debate

Testosterone declines approximately 1–2% per year after age 30. By age 70, many men have total testosterone below the young-adult reference range. Whether this constitutes "disease" requiring treatment or a normal physiologic process remains debated. Key points:

• The Endocrine Society recommends against routine testosterone testing in men >65 based on age alone
• Test only if specific hypogonadal symptoms are present
• The TTrials (Testosterone Trials, 2016) showed modest benefits in sexual function and a small improvement in walking distance in men ≥65 with low T, but no meaningful improvement in vitality or cognitive function
• The TRAVERSE trial established cardiovascular safety but also showed increased AF, AKI, and PE risk
• In older men, the benefit-risk calculus is narrower. Start with the lowest effective dose and monitor hematocrit closely (polycythemia risk is highest in older men).

Clomiphene Citrate: The Fertility-Preserving Alternative

Clomiphene citrate (off-label in men) is a selective estrogen receptor modulator (SERM) that blocks estrogen feedback at the hypothalamus and pituitary, increasing GnRH, LH, and FSH secretion, which in turn stimulates endogenous testosterone production and preserves spermatogenesis.

• Indication: Secondary hypogonadism in men who desire fertility, or as a trial before committing to TRT
• Typical dose: 25–50 mg daily or every other day
• Monitoring: Total testosterone, LH, estradiol at 4–6 weeks. Adjust dose to achieve mid-normal testosterone without excessive estradiol.
• Advantages: Oral, inexpensive, preserves spermatogenesis, reversible
• Limitations: Not FDA-approved for male hypogonadism (off-label). May not be as effective as TRT for symptom relief. Elevated estradiol can cause gynecomastia. Contraindicated in primary hypogonadism (LH is already high—stimulating it further won't help).

The "Testosterone Clinic" Phenomenon and Scope of Practice

What You're Seeing in Practice

Patients are arriving at primary care already on TRT prescribed by telehealth or "men's health optimization" clinics, often without proper diagnostic workup. Common problems you'll encounter:

• Started on TRT without two confirmed low morning testosterone levels
• No LH/FSH checked (so primary vs. secondary was never classified, and treatable causes like prolactinoma were never evaluated)
• No baseline PSA or hematocrit
• Concurrent anastrozole prescribed routinely (not guideline-recommended; lowers estradiol and may worsen bone density)
• Concurrent hCG prescribed to "maintain fertility"—partially effective but adds cost and complexity
• Supraphysiologic dosing targeting the "high-normal" range or above
• No monitoring of hematocrit (polycythemia developing silently)

Your role: Don't reflexively discontinue their TRT, but do complete the workup that was skipped. Check LH/FSH (will be suppressed on TRT, but establish the record), PSA, hematocrit, and estradiol. Verify the indication was legitimate. Adjust to guideline-concordant dosing and monitoring.

The Pitfalls

• Drawing testosterone in the afternoon: The #1 collection error. An afternoon level can be 20–25% lower than the morning peak. Always 6–10 AM, fasting.
• Using a single low level to diagnose: The Endocrine Society requires two confirmed low morning levels. Up to 30% of men normalize on repeat testing.
• Ignoring SHBG in obese/diabetic men: Total testosterone is artificially low when SHBG is low. Check free testosterone before diagnosing.
• Skipping LH/FSH: This misses prolactinoma, hemochromatosis, and Klinefelter syndrome—all of which have specific treatments.
• Prescribing TRT to a man who wants children: TRT is a contraceptive. It suppresses spermatogenesis. Recovery after discontinuation is unpredictable (months to >1 year; some men have permanent impairment). Use clomiphene or hCG instead.
• Not monitoring hematocrit: Polycythemia is the most common adverse effect. Hematocrit >54% requires intervention (dose reduction, therapeutic phlebotomy, or discontinuation).
• Treating "low-normal" testosterone in the absence of symptoms: A total testosterone of 350 in a 60-year-old man who feels well, has normal libido, and has no metabolic risk factors does not require treatment. Treat the patient, not the number.
• Routine aromatase inhibitor use: Anastrozole to "manage estrogen" is not recommended by the Endocrine Society or AUA guidelines outside of specific clinical scenarios. It lowers estradiol, which is important for bone health and cardiovascular protection.
• Forgetting the transference risk: Topical testosterone gel can transfer to women and children through skin contact, causing virilization. FDA black box warning. Counsel on application, hand washing, covering the site, and laundering clothing/bedding.
• Missing the opioid connection: Chronic opioid use causes secondary hypogonadism in the majority of men. Check testosterone before attributing sexual dysfunction to "age" in a patient on chronic opioids.

NP Prescribing Considerations

Testosterone is a Schedule III controlled substance (DEA). NP prescriptive authority for controlled substances varies by state. Before prescribing:

• Verify your state scope-of-practice allows Schedule III prescribing (most states permit this for NPs, but some require collaborative agreement specifics)
• Testosterone cypionate/enanthate for injection is the most cost-effective option (generic, widely available)
• Document the diagnostic criteria clearly: two confirmed low morning testosterone levels + symptoms + classification (primary vs. secondary) + absence of contraindications
• Document that reversible causes were addressed (weight loss counseling in obesity, opioid taper consideration, sleep apnea treatment)
• Set expectations with the patient: symptom improvement takes 3–12 months depending on the symptom (libido and energy improve faster than body composition and bone density)
• Schedule follow-up labs at 3 months and 6 months, then annually

Bottom Line

Testosterone testing requires the right collection (morning, fasting, two samples), the right interpretation (consider SHBG in obese/diabetic men), and the right classification (LH/FSH to distinguish primary from secondary). Before prescribing TRT, check PSA, hematocrit, and prolactin; rule out treatable causes like prolactinoma and hemochromatosis; confirm the patient doesn't want fertility; and ensure reversible contributors like obesity and opioids are addressed. Monitor hematocrit religiously—polycythemia is the most common and most dangerous adverse effect. And when a patient arrives already on TRT from an outside clinic, don't panic—just do the workup that should have been done from the start.

Stay sharp out there.

Urine Cultures: Outpatient vs. Inpatient Interpretation, When to Treat, and When to Leave the Bacteria Alone

Urine Cultures: Outpatient vs. Inpatient Interpretation, When to Treat, and When to Leave the Bacteria Alone

Asymptomatic bacteriuria in a 78-year-old with a positive culture is not a UTI. Treating it breeds resistance and helps no one.

Urine cultures are among the most frequently ordered and most frequently misinterpreted tests in all of medicine. The central problem is this: bacteria in the urine doesn't always mean infection, and a positive culture doesn't always require treatment. The rules for interpretation differ based on collection method, patient population, symptoms, and clinical setting. Getting this wrong in either direction—treating colonization or missing true infection—has real consequences.

What the Culture Report Tells You

A urine culture report includes three components:

• Organism identification: Which bacteria grew (e.g., E. coli, Klebsiella, Enterococcus, Proteus)
• Colony count (CFU/mL): Quantifies the bacterial burden. The traditional threshold for “significant” bacteriuria is ≥10⁵ CFU/mL (100,000), but this varies by context.
• Sensitivity panel: Which antibiotics the organism is susceptible, intermediate, or resistant to

Thresholds: When Is the Colony Count “Significant”?

Collection Method	Significant Threshold	Notes
Clean-catch midstream	≥105 CFU/mL (single organism)	The classic Kass criteria. In symptomatic women, ≥103 (1,000) CFU/mL of a uropathogen may be clinically significant.
Catheterized specimen (in-and-out cath)	≥103–104 CFU/mL	Lower threshold because catheterization bypasses contamination from the periurethral area.
Indwelling catheter (Foley)	≥103 CFU/mL	But presence of bacteria in a catheterized patient is expected (catheter-associated bacteriuria develops in ~3–5% of patients per day). Only treat if symptomatic (see CAUTI criteria below).
Suprapubic aspiration	Any growth	This is a sterile collection. Any organism is significant.

The Symptomatic Threshold

In a symptomatic woman with dysuria, frequency, and urgency, a colony count of 10³ CFU/mL (1,000) of E. coli is clinically significant and warrants treatment. The rigid 10⁵ threshold was established in 1960 for asymptomatic screening and overestimates the threshold needed for symptomatic infection. Clinical symptoms + a uropathogen at ≥10³ CFU/mL = UTI. Don't dismiss a symptomatic patient because the culture “only” grew 10,000 colonies.

Outpatient Urine Culture: When to Order, When to Skip

Uncomplicated UTI in Premenopausal Women

This is the most common UTI scenario in primary care, and it usually does NOT require a culture:

• Diagnosis: Clinical (dysuria + frequency + urgency ± hematuria, absence of vaginal discharge). Positive UA (leukocyte esterase, nitrites, pyuria) supports the diagnosis but is not required.
• Culture: Not routinely needed for uncomplicated cystitis. Empiric treatment based on local resistance patterns.
• When to culture: Treatment failure (symptoms persist after 48–72 hours on appropriate antibiotic), recurrent UTI (≥3 per year or ≥2 in 6 months), atypical symptoms, recent antibiotic exposure (risk of resistant organism), or suspected pyelonephritis.

Complicated UTI (Culture ALWAYS Indicated)

A complicated UTI = infection in the setting of a structural or functional urinary tract abnormality, or host factors that increase the risk of treatment failure:

• Men (any UTI in a male is complicated until proven otherwise)
• Pregnancy
• Urinary catheter or recent instrumentation
• Urologic abnormalities (obstruction, stones, stent, neurogenic bladder)
• Renal transplant
• Immunocompromised patients
• Diabetes (debated; some guidelines include, some exclude)
• Suspected pyelonephritis (flank pain, fever, CVA tenderness)
• Recent hospitalization or healthcare facility exposure (risk for MDR organisms)

Outpatient Empiric Treatment Guide

Uncomplicated cystitis first-line (IDSA 2011 guidelines, still current):

• Nitrofurantoin monohydrate/macrocrystals (Macrobid) 100 mg BID × 5 days (avoid if CrCl <30)
• TMP-SMX DS BID × 3 days (if local resistance <20%; check your antibiogram)
• Fosfomycin 3 g single dose (slightly less effective than above but useful for MDR)

Do NOT use fluoroquinolones for uncomplicated cystitis. FDA black box warnings for tendinopathy, neuropathy, and aortic dissection. Reserve for pyelonephritis or complicated UTI when no safer alternative exists.

The Asymptomatic Bacteriuria Problem

The Most Overtreated Non-Disease in Medicine

Asymptomatic bacteriuria (ASB) = bacteria in the urine (≥10⁵ CFU/mL) WITHOUT urinary symptoms. It is common: found in 3–5% of premenopausal women, 6–16% of women >65, 15–50% of nursing home residents, and nearly 100% of patients with chronic indwelling catheters. It should NOT be treated in the vast majority of patients. Treatment of ASB does not reduce symptoms (there are none), does not prevent future UTIs, and DOES breed antibiotic resistance.

Screen and Treat ASB ONLY In:

• Pregnancy: ASB in pregnancy increases risk of pyelonephritis (20–40% if untreated). Screen with urine culture at first prenatal visit (12–16 weeks). Treat based on sensitivities. Recheck culture after treatment.
• Before urologic procedures that involve mucosal trauma (TURP, cystoscopy with biopsy). Screen and treat to prevent bacteremia.

Do NOT Screen or Treat ASB In:

• Non-pregnant women (premenopausal or postmenopausal)
• Elderly patients (including nursing home residents)
• Patients with diabetes
• Patients with spinal cord injuries
• Patients with indwelling catheters (TREAT ONLY if symptomatic CAUTI criteria met)
• Patients with renal transplant (beyond the initial post-transplant period—guidelines vary)

The Nursing Home Trap

This is where the most harm occurs. A nursing home resident is confused (baseline). Someone orders a UA. It shows bacteria (expected in 30–50% of nursing home residents). The bacteria gets treated with antibiotics. The antibiotics cause C. difficile colitis. The colitis causes hospitalization. The hospitalization leads to deconditioning, falls, and further cognitive decline. The entire cascade started with treating bacteria that weren't causing disease. In the elderly, confusion alone is NOT a UTI symptom unless new-onset and temporally associated with new urinary symptoms (dysuria, frequency, urgency, suprapubic pain, gross hematuria). Chronic indwelling catheter + bacteriuria ≠ UTI.

Inpatient Urine Culture Interpretation

CAUTI: Catheter-Associated UTI

CAUTI is a specific diagnosis with strict criteria (per IDSA 2010 and CMS/NHSN definitions):

• Indwelling urinary catheter in place for >2 calendar days (day of insertion = day 1), with catheter in place on the date of the event OR removed the day before
• At least ONE of: fever >38°C, suprapubic tenderness, costovertebral angle tenderness, urinary urgency, frequency, or dysuria (in recently decatheterized patients)
• Urine culture with ≥10³ CFU/mL of ≤2 organisms
• CAUTI cannot be diagnosed by positive UA or culture alone. Pyuria in a catheterized patient is expected and does not distinguish infection from colonization.

Hospital-Acquired UTI (Non-Catheter)

• Culture obtained >48 hours after admission (or >48 hours after catheter removal)
• Symptomatic + positive culture
• Consider hospital-acquired pathogens: Pseudomonas, ESBL-producing E. coli/Klebsiella, Enterococcus, Candida

Candiduria

Candida in the urine is almost always colonization in catheterized patients. Treat ONLY if:

• Symptomatic (fever without other source + candiduria)
• Neutropenic patient (candiduria may indicate disseminated candidiasis)
• Renal transplant recipient
• Undergoing urologic procedure

First step for asymptomatic candiduria: remove or change the catheter. Candiduria often resolves.

Outpatient vs. Inpatient: The Key Differences

Factor	Outpatient	Inpatient
Most common pathogen	E. coli (~75–90% of uncomplicated UTIs)	E. coli still most common, but higher rates of Enterococcus, Pseudomonas, Klebsiella, Candida
Resistance patterns	Use community antibiogram. TMP-SMX resistance varies (10–30% regionally). Nitrofurantoin resistance remains low (<5%).	Higher MDR rates. ESBL prevalence increasing. Always culture and use sensitivity-directed therapy.
Culture indication	Not needed for uncomplicated cystitis. Always for complicated UTI, recurrent UTI, pyelonephritis.	Always. Empiric treatment started but adjusted based on culture.
ASB management	Don't screen, don't treat (except pregnancy and pre-urologic procedure).	Don't screen, don't treat. Positive cultures in catheterized patients without symptoms ≠ CAUTI.
Empiric antibiotics	Nitrofurantoin or TMP-SMX for cystitis. Fluoroquinolone or ceftriaxone for pyelonephritis.	Broader coverage: ceftriaxone, piperacillin-tazobactam, or carbapenem depending on local resistance and patient risk factors. Narrow based on culture.
Treatment duration	Uncomplicated cystitis: 3–5 days. Pyelonephritis: 5–7 days (fluoroquinolone) or 10–14 days (beta-lactam).	CAUTI: 7 days typical (shorter if catheter removed and rapid response). Pyelonephritis/urosepsis: 7–14 days with step-down to oral when stable.

Reading the Sensitivity Panel

Practical Sensitivity Interpretation

• S (Susceptible): Standard dosing should be effective
• I (Intermediate): May be effective at higher doses or in sites of concentration (urine concentrates many antibiotics, so “I” for a urinary isolate may actually work—discuss with pharmacy/ID)
• R (Resistant): Don't use it
• SDD (Susceptible-Dose Dependent): Newer CLSI category for some beta-lactams. Effective with higher doses or extended infusions.

Choose the narrowest effective antibiotic. If nitrofurantoin shows S for an outpatient cystitis, use it—don't jump to a fluoroquinolone. Antibiotic stewardship starts at the sensitivity panel.

Special Populations

Pregnancy

• Screen for ASB with urine culture at first prenatal visit. Treat if positive.
• Safe antibiotics: Nitrofurantoin (avoid at term/near delivery due to theoretical hemolysis risk in G6PD-deficient neonate), amoxicillin-clavulanate, cephalexin, fosfomycin
• Avoid: Fluoroquinolones (cartilage toxicity), TMP-SMX (folate antagonism in 1st trimester, kernicterus risk at term)
• Repeat culture after treatment to confirm clearance. Monthly surveillance cultures through delivery if history of recurrent UTI.

Men

• Any UTI in a male is considered complicated. Always culture.
• Evaluate for structural cause if recurrent: prostate assessment, post-void residual, imaging if indicated
• Treatment is longer: 7–14 days for cystitis (fluoroquinolone or TMP-SMX preferred for prostatic penetration). Nitrofurantoin does NOT penetrate the prostate.

Pediatric

• Clean-catch is unreliable in non-toilet-trained children. Catheterized specimen or suprapubic aspiration is preferred for culture.
• Bagged specimens have high contamination rates and should only be used for screening (if negative, it's helpful; if positive, confirm with cath specimen).
• First febrile UTI in a child <24 months: renal-bladder ultrasound. VCUG for recurrent febrile UTI or abnormal ultrasound.
• Threshold for catheterized specimen in children: ≥5 × 10⁴ CFU/mL

Mixed Flora and Contamination

• “Mixed flora” or ≥3 organisms: Almost always contamination from a poor clean-catch technique. Repeat with better collection.
• Two organisms with one dominant: May be significant, especially in complicated or catheterized patients. Interpret in clinical context.
• Lactobacillus, coagulase-negative Staphylococcus (except S. saprophyticus), diphtheroids: Usually contaminants.
• Staphylococcus saprophyticus: A true uropathogen in young sexually active women. The second most common cause of uncomplicated UTI after E. coli. Characteristically nitrite-negative on UA (it doesn't convert nitrate to nitrite).

The Pitfalls

• Treating asymptomatic bacteriuria in the elderly: The most common and most harmful error. Bacteria in the urine ≠ UTI. Symptoms are required.
• Using UA alone to diagnose UTI: Positive leukocyte esterase and nitrites support UTI but are not diagnostic alone. Pyuria without symptoms is not UTI. Negative nitrites don't exclude UTI (Enterococcus, Pseudomonas, Candida, and S. saprophyticus are nitrite-negative).
• Ordering cultures on every outpatient cystitis: Uncomplicated cystitis in premenopausal women doesn't need a culture. It drives up cost and antibiotic changes based on sensitivity data that weren't needed.
• Treating positive cultures in catheterized patients without symptoms: Catheter-associated bacteriuria is universal. Only treat CAUTI, not colonization.
• Nitrofurantoin for pyelonephritis: Nitrofurantoin concentrates in the urine but does NOT achieve adequate tissue or serum levels. It treats cystitis only—never pyelonephritis, never urosepsis.
• Ignoring the local antibiogram: Community resistance patterns vary enormously. In some regions, TMP-SMX resistance exceeds 30%—making it a poor empiric choice. Know your local data.
• Reflexively treating low colony counts as contamination: A symptomatic woman with 10³–10⁴ CFU/mL of E. coli on a clean-catch has a UTI. The 10⁵ threshold was never meant for symptomatic patients.

Bottom Line

A positive urine culture is a lab result, not a diagnosis. The diagnosis of UTI requires symptoms. In outpatient uncomplicated cystitis, empiric treatment without culture is appropriate. In complicated UTI, pregnancy, recurrence, or inpatient settings, always culture and treat based on sensitivities. Asymptomatic bacteriuria is treated only in pregnancy and before urologic procedures—nowhere else. And in the hospital, a positive culture in a catheterized patient without fever, pain, or new symptoms is colonization, not CAUTI. The hardest part of urine culture interpretation isn't reading the sensitivity panel—it's knowing when not to treat.

Stay sharp out there.

 

Tick Bite Workup: Geography Drives the Differential, and Timing Determines the Test

Don’t order Lyme titers the day after a tick bite. They’ll be negative. And don’t order them at all if the patient was bitten in Oklahoma.

Tick-borne illness is one of primary care's most geography-dependent diagnoses. The tick species, the pathogen it carries, the region where the bite occurred, and the timing of your lab work all determine whether you'll catch the diagnosis or miss it entirely. This post maps out which diseases to suspect based on location, when to test, what tests to order, and—critically—when to treat empirically before labs come back.

Step One: Identify the Tick and the Geography

Tick Species	Common Name	Primary Geography	Diseases Transmitted
Ixodes scapularis	Blacklegged tick / Deer tick	Northeast, upper Midwest, mid-Atlantic (CT, MA, NY, NJ, PA, MN, WI)	Lyme disease, Anaplasmosis, Babesiosis, Powassan virus, B. miyamotoi relapsing fever
Ixodes pacificus	Western blacklegged tick	Pacific Coast (CA, OR, WA)	Lyme disease (lower incidence than East Coast), Anaplasmosis
Amblyomma americanum	Lone Star tick	Southeast, south-central US (TX, OK, AR, MO, TN, NC, VA, FL)	Ehrlichiosis, STARI (Southern Tick-Associated Rash Illness), Heartland virus, Bourbon virus, Alpha-gal syndrome
Dermacentor variabilis	American Dog tick	East of Rocky Mountains, Pacific Coast	Rocky Mountain Spotted Fever (RMSF), Tularemia
Dermacentor andersoni	Rocky Mountain Wood tick	Rocky Mountain states (MT, WY, CO, ID)	RMSF, Colorado Tick Fever, Tularemia
Amblyomma maculatum	Gulf Coast tick	Gulf Coast states, expanding northward	Rickettsia parkeri rickettsiosis (milder cousin of RMSF, often with eschar at bite site)

Geography Is Your Differential

A febrile patient with a tick bite in Connecticut = think Lyme, Anaplasmosis, Babesiosis. A febrile patient with a tick bite in North Carolina = think RMSF, Ehrlichiosis, STARI. A febrile patient with a tick bite in Oklahoma or Arkansas = RMSF and Ehrlichiosis dominate; Lyme disease is exceedingly rare. Always ask where the bite occurred, not just where the patient lives. Travel history changes everything.

The Major Tick-Borne Diseases: Lab Workup and Timing

Lyme Disease (Borrelia burgdorferi)

Stage	Timing	Clinical Presentation	Lab Approach
Early Localized	3–30 days post-bite	Erythema migrans (EM) — expanding bull's-eye rash ≥5 cm. May have flu-like symptoms.	DO NOT order serology. Diagnose CLINICALLY. EM is pathognomonic. Serology is negative in up to 60% of early localized disease. Treat empirically: doxycycline 100 mg BID × 10–21 days.
Early Disseminated	Weeks to months	Multiple EM lesions, facial palsy (CN VII), carditis (heart block), meningitis, radiculopathy	Two-tier testing: EIA/ELISA (screening) → if positive/equivocal, confirmatory Western blot (IgM if <30 days of symptoms, IgM + IgG if >30 days). OR the newer modified two-tier (MTTT): EIA #1 → EIA #2 (no Western blot). Serology is ~70–80% sensitive at this stage.
Late Disseminated	Months to years	Lyme arthritis (large joint, especially knee), late neurologic Lyme (encephalopathy, polyneuropathy)	IgG serology is almost always positive at this stage (>95% sensitivity). IgM alone is NOT sufficient for late disease—IgM positivity without IgG in late Lyme is likely a false positive.

The Timing Trap

Lyme serology takes 2–6 weeks to become positive after infection. Ordering Lyme titers the day after a tick bite—or even the day the EM rash appears—will be negative and gives false reassurance. In early localized Lyme (EM rash), the diagnosis is clinical and the treatment is empiric. Serology is for disseminated disease when the clinical picture is compatible but the EM rash was missed or absent.

Prophylaxis After Tick Bite (The 72-Hour Window)

Single-dose doxycycline 200 mg PO can be offered for Lyme prophylaxis if ALL of the following are met:

• The tick is identified as Ixodes scapularis (deer tick)
• The bite occurred in a Lyme-endemic area
• The tick was attached for ≥36 hours (engorged appearance)
• Prophylaxis can be given within 72 hours of tick removal
• No contraindication to doxycycline (pregnancy, age <8—though recent evidence supports doxycycline in shorter courses for children)

If any criterion is not met, observe without prophylaxis. Monitor for EM rash for 30 days.

Rocky Mountain Spotted Fever (Rickettsia rickettsii)

Treat First, Test Later

RMSF has a case fatality rate of 20–25% if untreated and can kill within days. Do NOT wait for lab confirmation to treat. If the clinical picture is compatible (fever + headache + myalgia ± rash in a tick-exposed patient in an endemic area), start doxycycline immediately—adults AND children of any age. The rash (petechial, starting on wrists/ankles, spreading centrally) may not appear until day 3–5 or may be absent in 10–15% of cases. Delaying treatment until the rash appears or until labs confirm increases mortality dramatically.

• Diagnosis: IFA (Indirect Fluorescent Antibody) for R. rickettsii IgG—paired sera (acute + convalescent 2–4 weeks later). A 4-fold rise confirms the diagnosis. The acute sample is almost always negative. Diagnosis is typically retrospective.
• CBC pattern: Thrombocytopenia, leukopenia (or normal WBC), elevated LDH, hyponatremia, elevated transaminases
• Geography: Despite the name, most cases occur in the southeast and south-central US (NC, TN, OK, AR, MO), not the Rocky Mountains. Also seen in tribal lands of the Southwest (Arizona).
• Treatment: Doxycycline 100 mg BID (adults) or 2.2 mg/kg BID (children) for 5–7 days or until afebrile ≥3 days.

Anaplasmosis (Anaplasma phagocytophilum)

• Vector: Ixodes scapularis (same tick as Lyme—co-infection is common)
• Geography: Northeast, upper Midwest (overlaps Lyme belt)
• Presentation: Fever, headache, myalgia, malaise. NO rash (or rash is rare). 1–2 weeks after bite.
• Lab pattern: Leukopenia + thrombocytopenia + elevated transaminases—this triad in a febrile patient from an endemic area is Anaplasmosis until proven otherwise.
• Diagnosis: Peripheral blood smear showing morulae (intracytoplasmic inclusions in neutrophils)—seen in 20–80% of cases. PCR (most sensitive in first week). IFA serology (paired sera; same timing issues as RMSF).
• Treatment: Doxycycline. Empiric treatment for the leukopenia/thrombocytopenia/transaminitis triad while awaiting confirmation.

Ehrlichiosis (Ehrlichia chaffeensis)

• Vector: Amblyomma americanum (Lone Star tick)
• Geography: Southeast, south-central US
• Presentation: Clinically identical to Anaplasmosis. Fever, headache, myalgia. Rash more common than Anaplasmosis (~30%) but still not reliable.
• Lab pattern: Same triad: leukopenia + thrombocytopenia + elevated transaminases
• Diagnosis: Morulae in monocytes (not neutrophils—that's the distinction from Anaplasmosis). PCR, IFA serology.
• Treatment: Doxycycline.

Babesiosis (Babesia microti)

• Vector: Ixodes scapularis (co-infection with Lyme and Anaplasmosis possible)
• Geography: Northeast and upper Midwest (concentrated in southern New England and NY)
• Presentation: Fever, fatigue, hemolytic anemia. Can be severe in asplenic, immunocompromised, or elderly patients.
• Lab pattern: Hemolytic anemia (elevated LDH, low haptoglobin, elevated indirect bilirubin, reticulocytosis) + thrombocytopenia
• Diagnosis: Thin blood smear showing intraerythrocytic ring forms (look like malaria—pathology must be alerted to consider Babesia). PCR. IFA serology.
• Treatment: Atovaquone + azithromycin (mild/moderate). Clindamycin + quinine (severe). NOT doxycycline—Babesia is a parasite, not a bacterium.

The Co-Infection Problem

Same Tick, Multiple Pathogens

Ixodes scapularis can carry Lyme, Anaplasmosis, and Babesiosis simultaneously. A single tick bite can transmit more than one pathogen. Suspect co-infection when a Lyme patient doesn't respond to doxycycline as expected, has persistent high fevers (uncommon in Lyme alone), has hemolytic anemia (Babesiosis), or has the leukopenia/thrombocytopenia/transaminitis triad (Anaplasmosis). When treating Lyme in the northeast, have a low threshold to check CBC, smear, and liver enzymes for co-infection.

Alpha-Gal Syndrome: The Lone Star Tick Surprise

The Lone Star tick (Amblyomma americanum) can sensitize patients to alpha-gal, a carbohydrate found in mammalian meat (beef, pork, lamb). This causes a delayed IgE-mediated allergic reaction 3–6 hours after eating red meat.

• Presentation: Urticaria, angioedema, GI symptoms, or anaphylaxis occurring 3–6 hours after eating mammalian meat. The delay makes the connection non-obvious.
• Diagnosis: Alpha-gal IgE (specific IgE to galactose-alpha-1,3-galactose). Total tryptase if anaphylaxis suspected.
• Geography: Southeast US (Lone Star territory), expanding northward
• Management: Avoidance of mammalian meat and products (some patients also react to dairy, gelatin, or medications in gelatin capsules). EpiPen prescription for those with history of anaphylaxis.

STARI: The Lyme Look-Alike of the South

Southern Tick-Associated Rash Illness (STARI) presents with an EM-like expanding rash after a Lone Star tick bite in the southeastern US. It is NOT Lyme disease—B. burgdorferi is not transmitted by Lone Star ticks. The causative agent remains unidentified. STARI is milder than Lyme, does not cause the disseminated complications (carditis, arthritis, neurologic disease), and is generally treated empirically with doxycycline. The clinical pearl: an EM-like rash in Georgia or Texas is STARI, not Lyme. Don't order Lyme serology in non-endemic areas.

Timing Summary: When to Order What

Scenario	Lab Approach	Timing
Asymptomatic tick bite, tick just removed	No labs. Observe for 30 days. Prophylaxis if criteria met (see above).	N/A
EM rash present	No serology needed. Diagnose clinically. Treat with doxycycline.	Day of diagnosis
Fever + tick exposure, endemic for RMSF/Ehrlichiosis	CBC, CMP, start doxycycline empirically. Draw acute serology (IFA) but don't wait for results. Convalescent titers in 2–4 weeks.	Treat immediately. Labs are retrospective.
Suspected disseminated Lyme (facial palsy, carditis, arthritis)	Two-tier serology (EIA/ELISA → Western blot or MTTT). Sensitivity ~70–95% depending on stage.	≥2–4 weeks after infection for IgM; ≥4–6 weeks for IgG
Suspected Anaplasmosis/Ehrlichiosis	CBC (leukopenia + thrombocytopenia + elevated LFTs), blood smear for morulae, PCR (first week), IFA (paired sera)	PCR best in first week of illness. Serology requires convalescent sample.
Suspected Babesiosis	Thin blood smear, PCR, CBC (hemolytic anemia pattern), IFA serology	Smear and PCR at presentation. Serology takes weeks.
Suspected alpha-gal	Alpha-gal specific IgE	Anytime after sensitization (weeks to months post-bite)

The Pitfalls

• Ordering Lyme serology too early: The #1 error. Serology is negative in the first 1–3 weeks. EM rash is a clinical diagnosis. A negative titer at day 5 rules out nothing.
• Ordering Lyme serology in non-endemic areas: Lyme is concentrated in the Northeast and upper Midwest. A positive Lyme titer in a patient bitten in Alabama is almost certainly a false positive. Geography first, labs second.
• Waiting for labs to treat RMSF: This kills people. Doxycycline is the treatment for all suspected rickettsial disease, and it should be started on clinical suspicion alone. The labs confirm the diagnosis after the fact.
• Forgetting co-infection: A Lyme patient in Connecticut who isn't improving on doxycycline may have concurrent Babesiosis (which doesn't respond to doxycycline). Check the smear.
• IgM-only positivity in late Lyme: If symptoms have been present for >30 days and IgG is negative but IgM is positive, this is most likely a false positive IgM, not late Lyme disease.
• Checking “Lyme titers” as a screening test for chronic fatigue: Lyme serology is not a screening tool for nonspecific symptoms. It has a 5% false positive rate. In low-probability patients, a positive result is more likely false than true (Bayesian reasoning).
• Doxycycline in children: The AAP and CDC now endorse doxycycline for children of ALL ages for tick-borne illness. Short courses (≤21 days) do not cause dental staining. Do not withhold doxycycline from a child with suspected RMSF.
• Missing the Lone Star tick expanding range: Amblyomma americanum is moving northward due to climate change. Ehrlichiosis and alpha-gal are appearing in areas that were previously non-endemic. Stay current on your local tick maps.

Bottom Line

Tick-borne illness workup starts with two questions: where was the patient bitten, and when? Geography determines the differential. Timing determines the test. EM rash = treat without labs. RMSF suspicion = treat before labs. Lyme serology is useless in the first 2 weeks and useless outside endemic areas. The leukopenia/thrombocytopenia/transaminitis triad points to Anaplasmosis or Ehrlichiosis. Hemolytic anemia after an Ixodes bite = Babesiosis. And doxycycline is safe for children. Know your ticks, know your geography, and when in doubt, give the doxycycline.

Stay sharp out there.